Tag
Early intervention for head and neck cancer-related lymphedema significantly improves swallowing function and patient-reported outcomes, supporting timely multidisciplinary care.
Recent evidence highlights the prognostic significance of body composition metrics, including BMI, skeletal muscle mass, and adiposity distribution, in head and neck cancer radiotherapy outcomes. Automated 3D CT phenotyping refines risk str
This review evaluates evidence linking perioperative cannabis use to prolonged opioid use and functional outcomes in head and neck cancer patients undergoing free flap reconstruction, emphasizing implications for pain management.
This study identifies a link between exposure to wildfire-specific PM2.5 air pollution and increased risks of head and neck cancers over a 10-year period, with notable effects on oral cavity, oropharyngeal, and laryngeal cancers.
A study at The Ohio State Comprehensive Cancer Center reveals high rates of prolonged opioid use following radiation or chemoradiation in head and neck cancer patients, underscoring the need for tailored opioid stewardship.
This study evaluates the development, implementation, and performance of EHR-integrated synoptic operative reporting templates in head and neck cancer surgery, highlighting improved documentation quality and variable adherence.
A meta-analysis reveals immune checkpoint inhibitors may reduce survival in head and neck squamous cell carcinoma patients with PD-L1 combined positive scores less than 1, signaling caution in this subgroup’s treatment.
A surgeon-led outpatient palliative care clinic for head and neck cancer patients demonstrated significant symptom improvement, prolonged survival, and high rates of home or hospice deaths, underscoring its value in multidisciplinary cancer
This study validates the MD Anderson Dysphagia Inventory (MDADI) as a reliable screening tool for VFSS-graded swallowing impairment in head and neck cancer patients and proposes a concise four-item version to optimize clinical utility.
Neoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.
A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.
The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.
This review synthesizes evidence on patients’ perceptions of telehealth for head and neck cancer surveillance, highlighting barriers, benefits, and the potential of hybrid models to improve acceptability post-treatment.
A genetic study reveals that higher blood manganese levels are significantly associated with increased risks of oral cavity and HPV-positive oropharyngeal squamous cell carcinomas, suggesting a novel biomarker and potential target for preve
This review synthesizes evidence on factors influencing delays in postoperative radiotherapy for head and neck cancer in rural settings, emphasizing communication, coordination, and community resources to inform strategies that improve care
This study found that patient-reported speech/voice and related head-and-neck symptoms can help predict hypoglossal neuropathy risk after oropharyngeal cancer treatment, supporting earlier surveillance with the MDASI-HN-NERVE score.
In patients with head and neck cancer, living in the most socioeconomically disadvantaged areas was associated with poorer pretreatment head and neck cancer–specific quality of life, while associations with other quality-of-life domains wer
In a retrospective cohort of 362 head and neck free tissue transfer patients, routine hospitalist involvement was associated with fewer transfers to a higher level of care, without significant effects on length of stay, readmission, or 90-d
In advanced head and neck squamous cell carcinoma, pretreatment weight loss and low prognostic nutritional index were linked to shorter progression-free survival after immunotherapy, while baseline BMI was not predictive.
A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific com
